Generic Name and Formulations:
Granisetron 3.1mg/24hrs; transdermal delivery system (patch).
Kyowa Kirin, Inc.
Indications for SANCUSO:
Prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
≥18yrs: apply one patch to clean, dry, intact healthy skin on upper outer arm 24 to 48 hours before chemotherapy; remove at least 24 hours after chemotherapy is completed. May wear patch for up to 7 days. Do not cut patch.
<18yrs: not recommended.
May mask progressive ilieus and/or gastric distention. Avoid direct sun or UV light (cover patch with clothing during use and for 10 days after removing patch). Avoid exposure to external heat sources (eg, heating pads). Pregnancy (Cat.B). Nursing mothers.
5-HT3 receptor antagonist.
Do not take with other granisetron products. Serotonin syndrome possible esp. with concomitant serotonergic drugs.
Constipation; local irritation (remove patch if severe or if generalized skin reaction occurs), headache; serotonin syndrome (discontinue if occurs).
Endocrinology Advisor Articles
- Behavioral Weight Loss Interventions May Prevent Obesity
- Association Between Urine Complement Proteins and Kidney Disease, Mortality in T2D
- PCSK9 Inhibition: Benefits Outweigh Risks in Patients With Diabetes
- Rates of Incident Type 2 Diabetes in Chronic Kidney Disease
- Availability and Affordability of Diabetes Medication Worldwide
- Bioethics Concerns Should Be a Key Element in mHealth Technology Development
- Gestational Diabetes Associated With Increased Risk for Postpartum Depression
- High Prevalence of Obstructive Sleep Apnea Syndrome May Favor Screening in Diabetes
- Update on the T2D-Dementia Link: Interview With Experts
- Dozens of Medical Groups Join Forces to Improve Diagnoses